GlassScriptPhysician profile
Catherine A Buerchner
NPI 1962465732
$1,737.88
in general payments reported to CMS, 2019-2025
23 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $30.61 · 2021: $44.33 · 2022: $76.47 · 2023: $207 · 2024: $781 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $367.01 | 2023-2024 | Veozah |
| Abbvie INC. | $231.08 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $152.35 | 2024-2025 | |
| Biogen, INC. | $118.36 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $112.22 | 2020-2024 | |
| Becton, Dickinson and Company | $106.12 | 2023-2024 | Arista Ah Flexitip, Bd Onclarity |
| Sumitomo Pharma America, INC. | $105.63 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $72.02 | 2019-2023 | |
| Hologic Sales and Service, LLC | $60.02 | 2024-2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay, Acessa Provu System |
| Amag Pharmaceuticals, INC. | $52.85 | 2019 | |
| Organon LLC | $48.36 | 2022-2024 | Nexplanon |
| Avion Pharmaceuticals | $40.72 | 2019-2021 | |
| Exeltis, USA INC. | $36.89 | 2019-2021 | |
| Duchesnay USA Incorporated | $33.49 | 2019 | |
| Therapeuticsmd, INC. | $32.25 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.30 | 2019 | |
| Daiichi Sankyo INC. | $27.81 | 2024 | Injectafer |
| Myovant Sciences INC. | $22.76 | 2022 | |
| Viiv Healthcare Company | $21.06 | 2024 | Apretude |
| Coopersurgical, INC. | $20.78 | 2022 | |
| Aspira Women'S Health INC | $18.04 | 2024 | Ova1 |
| Allergan, INC. | $15.07 | 2019 | |
| Minerva Surgical, INC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Buerchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.